Phase 3 N=120 Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Uterine Atony · Uterine Atony With Hemorrhage · Postpartum Hemorrhage
Primary: Quantitative Blood Loss — 840; 1051 milliliters — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=27 Cannabis Use in Cancer Patients
Solid Tumor, Adult
Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants
N/A N=12 Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Proportion of Enrolled Participants for Which we Are Able to Collect Data From the Medication Event Monitoring Systems (MEMS^TM) System for Two or More Cycles of…
Phase 4 N=19 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Dermatomyositis · Juvenile Dermatomyositis
Primary: Change From Baseline in Cutaneous Dermatomyositis at 6 Months — -9 units on a scale — p=< .001
Phase 2 N=120 Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] — -5.48; -37.97; -43.35 percent change from baseline — p=<.0001
N/A N=21 Myofascial and Articular Treatment of Adolescent Idiopathic Scoliosis
Scoliosis Idiopathic Adolescent Treatment
Primary: Cobb Angle — 18.9; 23.8 degrees
Phase 2 N=408 Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: Number of Participants With ≥1 Adverse Event (AE) — 17; 23; 90; 3 Participants
N/A N=15 Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Skin Laxity
Primary: Percentage of Participants With Baseline and 6 Month Face Photographs Correctly Identified by Two Blind Evaluators — 7 Participants
N/A N=210 Healing Touch After Cesarean
Pain, Postoperative · Anxiety · Postpartum Complication
Primary: Count of Participants Who Reported HIGH PAIN After the Intervention — 2; 7 Participants — p=.019
N/A N=75 Trim II for Noninvasive Lipolysis and Circumference Reduction of Abdomen.
Circumference Reduction of Abdomen
Primary: Evaluation of Change in Abdomen Circumference Using Tape Measurements in cm at the 3 Months Follow-up Visit Comparing to Baseline. — 89.5 CM
Phase 2 N=69 Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm
Phase 3 N=529 Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
Obesity
Primary: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) — 16.8; 10.3 Score on a scale — p=<0.0001
Phase 2 N=14 Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
AIDS-Related Burkitt Lymphoma · Atypical Burkitt/Burkitt-Like Lymphoma · High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Primary: Participants With a Response — 9 Participants
N/A N=67 RN-Led Palliative and Supportive Care Intervention
Acute Myeloid Leukemia
Primary: Feasibility and Acceptability — 128; 93; 54; 38 Participants
Phase 2 N=12 Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
Cutaneous Lichen Planus
Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants